Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur Urol. 2019 Mar;75(3):374-377. doi: 10.1016/j.eururo.2018.10.053. Epub 2018 Nov 9.

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.

Author information

1
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: d.osses@erasmusmc.nl.
2
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
3
Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Pathology, Toronto General Hospital, Toronto, Canada.

Abstract

We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could result in considerable reductions of M+ disease and mortality which if confirmed in larger datasets should trigger further discussion on pros/cons of PCa screening. PATIENT SUMMARY: In a cohort with 19yr of follow-up, we found indications for a more substantial reduction in metastatic disease and cancer-specific mortality in favor of prostate cancer screening than previously reported. If confirmed in larger cohorts, these findings should be considered in the ongoing discussion on harms and benefits of prostate cancer screening.

KEYWORDS:

Cancer-specific mortality; Metastatic disease; PSA-based screening; Prostate cancer

PMID:
30420254
DOI:
10.1016/j.eururo.2018.10.053
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center